铂类耐药的非小细胞肺癌的治疗策略

Treatment Strategy of Platinum-resistant Non-small Cell Lung Cancer

铂类化疗药物自问世以来是多种肿瘤治疗方案中必不可少的组成部分。在非小细胞肺癌(NSCLC)治疗中,以铂类为基础的化疗方案发挥着举足轻重的作用。随着病情进展,肿瘤细胞对化疗药物产生耐药,影响患者疗效和预后。分子基因检测技术的迅猛发展,为铂类耐药后的治疗提供了更多选择。本文旨在为NSCLC患者铂类耐药后的治疗提供一些思路。

Platinum-based chemotherapeutic drugs have been an essential component of many cancer treatment programs since their introduction. Platinum-based chemotherapy regimens play an important role in non-small cell lung cancer（NSCLC） treatment. As the disease progresses, tumor cells become resistant to chemotherapeutic drugs, which affects patients＇curative effect and prognosis. The rapid development of molecular gene detection technology has provided more options for the treatment of platinum-based drug resistance. This paper aims to provide some ideas for the treatment of NSCLC patients with platinum-based drug resistance.